5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 55.48▼ | 55.48▼ | 55.61▼ | 55.44▼ | 55.18▲ |
MA10 | 55.77▼ | 55.62▼ | 55.61▼ | 55.14▲ | 54.26▲ |
MA20 | 55.63▼ | 55.29▲ | 55.25▲ | 55.27▲ | 51.91▲ |
MA50 | 55.19▲ | 54.99▲ | 55.11▲ | 54.22▲ | 51.59▲ |
MA100 | 55.10▲ | 55.24▲ | 55.11▲ | 51.79▲ | 47.79▲ |
MA200 | 55.29▲ | 54.38▲ | 53.94▲ | 51.81▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.076▼ | -0.011▼ | 0.013▲ | -0.032▼ | 0.324▲ |
RSI | 45.150▼ | 51.022▲ | 51.082▲ | 53.684▲ | 60.473▲ |
STOCH | 23.334 | 29.257 | 44.712 | 67.970 | 79.639 |
WILL %R | -100.000▼ | -91.623▼ | -54.517 | -36.437 | -21.400▲ |
CCI | -100.713▼ | -62.472 | -31.055 | 67.951 | 88.125 |
Thursday, August 14, 2025 03:53 AM
US biotech Response Pharmaceuticals (Nasdaq: RSPN) has unveiled top-line Phase II results for its experimental obesity therapy RDX-002, aimed at helping patients maintain weight loss after ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 55.75 | 55.75 | 55.24 | 55.31 | 26,500 |
14/08/25 | 55.74 | 55.75 | 55.43 | 55.57 | 16,900 |
13/08/25 | 55.65 | 56.21 | 55.39 | 56.21 | 51,400 |
12/08/25 | 54.81 | 55.46 | 54.80 | 55.46 | 18,900 |
11/08/25 | 54.88 | 54.88 | 54.49 | 54.65 | 23,100 |
08/08/25 | 55.00 | 55.12 | 54.77 | 54.82 | 28,100 |
07/08/25 | 55.23 | 55.27 | 54.63 | 54.85 | 20,500 |
06/08/25 | 54.95 | 54.99 | 54.53 | 54.91 | 21,900 |
05/08/25 | 54.75 | 55.03 | 54.58 | 54.93 | 46,500 |
04/08/25 | 54.48 | 54.74 | 54.37 | 54.72 | 44,200 |
|
|
||||
|
|
||||
|
|